Today we'll discuss Baxter's third quarter 2025 results along with an update to our full year 2025 outlook and newly issued fourth quarter 2025 guidance. This morning, a press release was issued with our preliminary earnings results and updated outlook. I am pleased to be here for my first earnings call as CEO and look forward to getting to know everyone here better as the quarters progress. This is a business whose portfolio has proven resilient over its almost 100 year history, one that has delivered significant revenues and attractive operating margins and generated solid cash flow over the years.

These results reflect challenges in two divisions, the Infusion Therapies and Technologies division within the Medical Products & Therapies segment and the Injectables and Anesthesia division within the Pharmaceuticals segment. Of course, there have been challenges in certain areas that have hampered growth and consistent execution, and we expect our growth algorithm to continue to be pressured in the near-term. The Spectrum IQ LVP now operates on a shared gateway with Novum IQ Syringe, creating a cohesive user experience and is built for the future with EMR interoperability, enhanced software, and innovative analytical capabilities. It is from the basis of a strong balance sheet that we will be better able to invest in the business, support innovation, and deliver and return increased value to our shareholders.

This means focusing on improved cash flow and taking a consistent approach to our capital allocation objective. It is in this context that we and the Board intend to reduce the quarterly dividend to $0.01 per share, beginning with the dividend to be paid in January 2026. Earlier this month we rolled out Baxter GPS, our new growth and performance system aimed at driving continuous improvement and a growth and performance mindset. On the bottom line, total company adjusted earnings from continuing operations were $0.69 per share.

What went well
  • Third quarter global sales from continuing operations totaled $2.8 billion, up 5% on a reported basis and 2% operationally, with growth across nearly all divisions.
  • Adjusted earnings from continuing operations were $0.69 per share, exceeding bottom-line expectations driven by a favorable tax rate, positive pricing in select segments, Kidney Care TSA income, and lower non-operating expenses.
  • Advanced Surgery sales totaled $306 million and grew 11% globally on solid demand for hemostats and sealants, strong commercial execution across all regions, and steady procedure volumes.
  • The Healthcare Systems & Technologies (HST) segment showed improved performance, with CCS U.S. sales up 4% on double-digit Surgical Solutions growth and total U.S. capital orders for CCS up 30% year over year.
  • The Pharmaceuticals segment grew 7%, with Injectables and Anesthesia up 3% on high single-digit Anesthesia growth, and the company generated positive free cash flow of $126 million in the quarter on a strong September.
  • Management launched Baxter GPS, a new growth and performance system aimed at continuous improvement, and reported strong early followership across the enterprise.
What went wrong
  • Third quarter top-line performance came in lower than previously issued guidance, reflecting challenges in the Infusion Therapies and Technologies (ITT) division and the Injectables and Anesthesia division.
  • ITT sales declined 4% to $1 billion due to lower infusion pump sales tied to the shipment and installation hold on the Novum IQ Large Volume Pump, with the hold expected to remain in place beyond year-end and some customers electing returns or exchanges to Spectrum IQ.
  • U.S. Hospital IV Solutions demand remained below pre-Hurricane Helene levels and below the company's expectations, with recovery proceeding at a slower pace than originally anticipated.
  • Continued softness in certain Premix products persisted, related to changing IV infusion protocols and increased use of IV push in select U.S. hospital settings.
  • HST adjusted operating margin fell 460 basis points to 13.5% on higher tariff costs, increased R&D investment, and increased corporate allocation expenses following the Kidney Care sale.

Guidance Changes

MetricPeriodCurrent guidance
Quarterly dividendBeginning January 2026 payment$0.01 per share (Reduced to free up cash to accelerate deleveraging)
Novum IQ LVP shipment/installation holdBeyond 2025Hold expected to remain in place beyond year-end; no specific lift timing committed (Extended)
Q4 / FY2025 outlookQ4 and FY2025Updated outlook reflects continued infusion pump pressure, IV Solutions softness, and premix softness (Lowered top line)

Performance Breakdown

MetricYoYNote
Total continuing operations sales +5% reported, +2% operational Growth across nearly all divisions, partly offset by ITT and premix softness
MPT segment sales -1% operational Softness in Infusion Therapies and Technologies, slightly offset by strong Advanced Surgery demand
ITT division sales -4% Lower infusion pump sales from the Novum LVP ship/install hold and ongoing post-Hurricane Helene fluid conservation in U.S. Hospital IV Solutions
Advanced Surgery sales +11% Solid demand for hemostats and sealants, strong commercial execution, steady procedure volumes
HST segment sales +2% CCS growth driven by Surgical Solutions, Patient Support Systems, and Care Communications; Frontline Care up 1% on cardiology demand
HST adjusted operating margin -460 bps to 13.5% Higher tariff costs, increased R&D investment, and increased corporate allocation expenses post Kidney Care sale, partly offset by TSA income
MPT adjusted operating margin +50 bps to 20.5% Positive pricing, partly offset by lower sales volumes and higher manufacturing and supply costs
Pharmaceuticals segment sales +7% High single-digit Anesthesia growth and favorable injectables comparison versus prior-year supply constraints

Earnings Call Themes & Trends

TopicPrevious mentionCurrent periodTrend
Novum IQ LVP shipment/installation holdPreviously discussed holdHold expected beyond year-end; customers evaluating alternatives, some returning or switching to Spectrum IQ; no committed lift timingWorsening / prolonged
Post-Hurricane Helene IV fluid conservationPrior conservation discussedDemand still below pre-Helene levels; recovery slower than expected; some conservation likely to persist into 2026Persistent / slower recovery
Premix product softness / IV push shiftDiscussed last quarterContinued softness from IV infusion protocol changes and increased IV push use in U.S. hospitalsContinuing
Balance sheet deleveraging and capital allocationPrior deleveraging commitmentsDividend cut to $0.01 to accelerate deleveraging; M&A limited to future fold-in/tuck-in opportunitiesIntensifying focus
Continuous improvement culture (Baxter GPS)—Newly launched growth and performance system to drive efficiency and accountabilityNew initiative
Hospital capital spending—No slowdown observed; CCS U.S. capital orders up 30% year over year despite macro uncertaintyStable / robust

Q&A Summary

What is your vision for Baxter and can it grow on the top and bottom line in 2026 given the lower Q4 jumping-off point?
Focus is on three areas: stabilizing the business and driving execution, strengthening the balance sheet to enable future investment, and driving a continuous improvement culture via GPS. An Investor Day is planned for 2026 to lay out long-term strategy; the company is not providing 2026 guidance but anticipates growth as it aims to outpace its markets.
How do lower-margin growth drivers and mix factor into the bottom line and Q4 guidance?
Mix was a challenge, though Advanced Surgery is positive mix and performing strongly. Infusion pump sales will stay pressured pending Novum resolution, IV Solutions recovery is slower than expected with conservation likely into 2026, and premix softness continues; the drop-through to the bottom line is primarily a volume/supply-chain story rather than pass-through issues.
Why is Novum taking longer, do you need a redesign or FDA refiling, and how much of the guide change is from Novum?
The hold supports safe customer use while additional corrections to the field actions are developed; the company cannot commit to specific lift timing and expects it beyond 2025. Some customers have initiated returns or exchanges to Spectrum IQ, and the updated guidance reflects uncertainty around Novum, including various customer responses.
When might Baxter resume more M&A and how will you improve free cash flow to fund it?
First priority is strengthening the balance sheet and delevering while continuing to invest in innovation; M&A will be future fold-in/tuck-in opportunities rather than large strategic deals. Free cash flow was positive at $126 million in the quarter with Q4 expected to be strongest; cash headwinds this year stemmed from Hurricane Helene outlays, tariffs, and inventory, with an aspirational 80% cash conversion target going forward.
Why is IV fluid conservation persisting this long after Hurricane Helene, and what are you seeing in hospital CapEx given political uncertainty?
Customer buying patterns still reflect conservation, similar to a 2017 episode that took up to two years to recover; management remains confident in medium- and long-term IV Solutions strength. On hospital CapEx, no slowdown has been observed despite Washington uncertainty, with HST orders up roughly 30% year over year.
Is implied Q4 injectables down mid-teens and what drives the operating margin decline?
Pharma softness reflects a marketplace shift in premixes toward vials and IV push, mainly in the U.S., with international performance solid; the company is reinforcing premix clinical value and improving commercial execution. The overall operating margin guidance impact truly reflects the sales/volume declines flowing through operations.

More on Baxter International Inc

Reported 2025-10-30 · figures from the Baxter International Inc Q3 2025 earnings call.

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.